New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 13, 2014
10:33 EDTVNDA, UBNT, ZU, RAX, MNKD, ARWR, OLED, ICPT, RPTPOptions with decreasing implied volatility
Options with decreasing implied volatility: RPTP ARWR ZU ICPT MNKD UBNT OLED RAX UVXY VNDA
News For RPTP;ARWR;ZU;ICPT;MNKD;UBNT;OLED;RAX;VNDA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 19, 2014
10:17 EDTRAXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:48 EDTRAXRackspace coverage resumed with a Buy at Stifel
Target $56.
06:26 EDTICPTIntercept price target lowered to $475 from $693 at Citigroup
Citigroup lowered its price target for Intercept shares to $475 on expectations investor concerns around the company's liver fibrosis drug, OCA, will persist. Citi, however, says it remains a buyer of the stock. It believes the level of concern around OCAís cholesterol effect is overdone. The firm keeps a Buy rating on shares of Intercept.
05:41 EDTUBNTUbiquiti Networks initiated with a Sell at Goldman
Subscribe for More Information
December 18, 2014
06:33 EDTICPTIntercept coverage resumed with a Buy at Sterne Agee
Subscribe for More Information
December 16, 2014
11:31 EDTRAXRackspace looks to reduce reliance on Intel chips, Bloomberg says
Rackspace Hosting (RAX), which has been testing server computers based on IBM (IBM) Power chip designs, is looking to reduce its reliance on Intel (INTC) chips as it shifting to some server computers based on modified International Business Machine processors, says Bloomberg. Reference Link
December 15, 2014
10:10 EDTUBNTHigh option volume stocks:
High option volume stocks: RVBD AGCO FRO CRUS UBNT LH PAY PETM OREX KOS
08:58 EDTICPTIntercept reinstated with a Buy at BofA/Merrill
Subscribe for More Information
07:33 EDTARWRArrowhead submits IND for ARC-520 to begin Phase 2b studies
Arrowhead Research announced that it submitted an Investigational New Drug application to the U.S. Food and Drug Administration for ARC-520, itís drug candidate for the treatment of chronic hepatitis B virus infection. Arrowhead plans to submit additional clinical trial authorization applications with regulatory authorities in various jurisdictions in Europe and Asia. Pending national regulatory review and approval, Arrowhead intends to initiate two Phase 2b, multicenter, randomized, double-blind, placebo-controlled, multi-dose studies to determine the depth of hepatitis B surface antigen reduction following ARC-520 injection in combination with entecavir or tenofovir in patients with chronic immune active HBV infection. The Heparc-2002 study is planned to include patients who are negative for hepatitis B e-antigen at screening and the Heparc-2003 study is planned to include patients who are positive for HBeAg at screening. The primary objective is to evaluate the depth of HBsAg decline in response to multiple doses of ARC-520 compared to placebo in patients with chronic HBV infection as a measure of drug activity. Secondary objectives are to assess measures of safety and tolerability and to evaluate multi-dose pharmacokinetics of ARC-520 in patients with chronic HBV infection when co-administered with a fixed dose of entecavir or tenofovir, in addition to other exploratory safety and pharmacodynamic objectives.
December 12, 2014
10:01 EDTRAXOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: BreitBurn Energy (BBEP) downgraded to Hold from Buy at Wunderlich... CIBC (CM) downgraded to Underperform from Neutral at Credit Suisse... Costco (COST) downgraded to Neutral from Buy at Janney Capital... Discovery (DISCA) downgraded to Sector Perform from Outperform at RBC Capital... Emerald Oil (EOX) downgraded to Neutral from Accumulate at Global Hunter... Goodrich Petroleum (GDP) cut to Underweight on lower oil at JPMorgan... Hain Celestial (HAIN) downgraded to Sector Perform from Outperform at RBC Capital... Hovnanian (HOV) downgraded to Neutral from Buy at Compass Point... Mindray Medical (MR) downgraded to Underweight from Equal Weight at Morgan Stanley... Morgan Stanley (MS) downgraded to Neutral from Buy at Buckingham... Oracle (ORCL) resumed with a Neutral from Overweight at Piper Jaffray... Rackspace (RAX) downgraded to Underperform from Neutral at DA Davidson... Zayo Group (ZAYO) downgraded to Neutral from Buy at BTIG.
08:10 EDTRAXRackspace downgraded to Underperform from Neutral at DA Davidson
Subscribe for More Information
08:01 EDTMNKDPiper predicts two large-cap biotechs could be acquired in 2015
Subscribe for More Information
December 11, 2014
14:55 EDTRAXRackspace management to meet with William Blair
Subscribe for More Information
13:09 EDTARWRArrowhead mentioned positively by Agora Financial
Agora Financial believes investors can "double [their] money ó virtually overnight." and have a "realistic chance" to make "up to 10 times [their] money" by investing in Arrowhead Research, according to a new research report from the firm. Arrowhead shares are up nearly 10% to $5.98 in afternoon trading. Reference Link
08:57 EDTICPTLeerink major pharma & biotech analysts hold analyst/industry conference call
Subscribe for More Information
07:34 EDTRAXBarclays to hold a bus tour
Subscribe for More Information
December 8, 2014
10:42 EDTRPTPOptions with increasing implied volatility
Subscribe for More Information
10:16 EDTOLEDUniversal Display management to meet with JMP Securities
Subscribe for More Information
05:50 EDTMNKDStocks with implied volatility movement; AVNR MNKD
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use